Gilead to buy Immunomedics in $21B deal
Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the companies said on Sunday in a statement.
via FOX BUSINESS NEWS Markets
https://ift.tt/32nOYMu
0 Comments